Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Union européenne - français - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - chlorhydrate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agents antithrombotiques - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Co-Lisinopril-Mepha 10 mg/12.5 mg Comprimés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

co-lisinopril-mepha 10 mg/12.5 mg comprimés

mepha pharma ag - lisinoprilum, hydrochlorothiazidum - comprimés - lisinoprilum 10 mg à lisinoprilum dihydricum, hydrochlorothiazidum 12,5 mg, excipiens pro compresso. - hypertonie - synthetika

Co-Lisinopril-Mepha 20 mg/12.5 mg Comprimés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

co-lisinopril-mepha 20 mg/12.5 mg comprimés

mepha pharma ag - lisinoprilum, hydrochlorothiazidum - comprimés - lisinoprilum 20 mg à lisinoprilum dihydricum, hydrochlorothiazidum 12,5 mg, excipiens pro compresso. - hypertonie - synthetika

Xtandi Union européenne - français - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - néoplasmes prostatiques - la thérapie endocrinienne - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Union européenne - français - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - bésilate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agents antithrombotiques - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Élévation du segment st infarctus aigu du myocarde, en association avec de l'aas dans traitée médicalement les patients éligibles à un traitement thrombolytique. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pour de plus amples informations, veuillez vous reporter à la section 5.

Protopic Union européenne - français - EMA (European Medicines Agency)

protopic

leo pharma a/s - tacrolimus - dermatite atopique - d'autres préparations dermatologiques - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. survenant quatre fois ou plus par année), qui ont eu une réponse initiale à un maximum de six semaines de traitement, deux fois par jour l'onguent de tacrolimus (lésions effacé, presque effacé ou légèrement touchés).

Co-Lisinopril Spirig HC 10/12,5mg Comprimés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

co-lisinopril spirig hc 10/12,5mg comprimés

spirig healthcare ag - lisinoprilum, hydrochlorothiazidum - comprimés - lisinoprilum 10 mg à lisinoprilum dihydricum, hydrochlorothiazidum 12,5 mg, mannitolum 20 mg, calcium hydrogenophosphas dihydricus, maydis pour amylum, de la silice colloidalis anhydrica, magnésium stearas, pour compresso de la brume. - hypertonie - synthetika

Co-Lisinopril Spirig HC 20/12,5 mg Comprimés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

co-lisinopril spirig hc 20/12,5 mg comprimés

spirig healthcare ag - lisinoprilum, hydrochlorothiazidum - comprimés - lisinoprilum 20 mg à lisinoprilum dihydricum, hydrochlorothiazidum 12,5 mg, mannitolum 40 mg, calcium hydrogenophosphas dihydricus, maydis pour amylum, de la silice colloidalis anhydrica, magnésium stearas, pour compresso de la brume. - hypertonie - synthetika

SAMSCA Comprimé Canada - français - Health Canada

samsca comprimé

otsuka pharmaceutical co ltd - tolvaptan - comprimé - 15mg - tolvaptan 15mg - vasopressin antagonists

SAMSCA Comprimé Canada - français - Health Canada

samsca comprimé

otsuka pharmaceutical co ltd - tolvaptan - comprimé - 30mg - tolvaptan 30mg - vasopressin antagonists